Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244079 | 1.00 | POLB (0.68) | POLBMAPTKMT2ALMNAPRKCI | |
| SCHEMBL2244644 | 0.90 | POLB (0.64) | POLBMAPTKMT2ALMNAPRKCI | |
| SCHEMBL2244649 | 0.90 | POLB (0.64) | POLBMAPTKMT2ALMNAPRKCI | |
| SCHEMBL6328342 | 0.81 | PRKCI (0.65) | POLBMAPTKMT2ALMNAPRKCI | |
| SCHEMBL1467572 | 0.80 | PRKCI (0.58) | POLBMAPTKMT2ALMNAPRKCI | |
| SCHEMBL1467573 | 0.80 | PRKCI (0.58) | POLBMAPTKMT2ALMNAPRKCI | |
| SCHEMBL14378341 | 0.79 | PRKCI (0.62) | POLBPRKCITAS1R3TAS1R1RAB9A | |
| SCHEMBL29793780 | 0.79 | PRKCI (0.62) | MAPTPRKCITAS1R3TAS1R1RAB9A | |
| SCHEMBL102518 | 0.79 | PRKCI (0.62) | MAPTPRKCITAS1R3TAS1R1RAB9A | |
| SCHEMBL8292450 | 0.77 | MAPT (0.68) | POLBMAPTKMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| EP-2162433-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2121603-A2 | 6' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008147812-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1866292-A1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | Auckland Uniservices Limited (NZ) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006104406-A1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR3B | POLB 3225/4885MAPT 4412/4885KMT2A 3231/4885 |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | POLB 3775/4885MAPT 4295/4885KMT2A 2980/4885 |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | POLB 1092/4885MAPT 4035/4885KMT2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.